IntroductIon
B cells represent an important target for gene transfer because single gene defects impacting B-lineage function have significant roles in the pathogenesis of immunodeficiency and autoimmunity. 1 One B cell disorder predicted to benefit from safe strategies for gene delivery is X-linked agammaglobulinemia (XLA). XLA is an immunodeficiency caused by a recessive gene defect in Bruton's tyrosine kinase (Btk), 2 that results in a block in B cell development at the pro-B cell stage, reduced numbers of circulating B cells, and a near absence of antibody responses in affected males. 3 XLA is a good candidate for gene therapy for several reasons: a relatively high disease frequency, the ability to treat without interruption of clinical therapy, and a strong selective advantage for genecorrected cells. 4, 5 In order to facilitate such therapies, we focused on designing a lentiviral vector (LV) optimized to drive gene expression in primary B cells, with a special emphasis on vectors that mimic the expression profile of endogenous Btk.
Self-inactivating LVs (LV) comprise a promising gene delivery platform for treatment of genetic disorders, autoimmune diseases, and malignancies. In contrast to γ-retroviruses, LVs proficiently target nondividing cells such as multipotent hematopoietic stem cells (HSC) at low viral copy number. [6] [7] [8] Self-inactivating-LV also limit the risk of viral long-terminal repeat enhancer mutagenesis and concurrently permit the use of lineage-specific promoters. 9 Furthermore, there is evidence of less transcriptional silencing of internal promoters within integrated LV, and a reduced bias for integration near transcription start sites. 10 These combined features likely reduce the overall risk of viral enhancer-mutagenesis responsible for adverse events in several γ-retroviral clinical trials. 11, 12 Previous work has demonstrated efficient transgene expression with LV utilizing a range of internal promoter and other regulatory elements. 8, 13, 14 To decrease potential side effects of nonspecific transgene expression in HSC-derived lineages, various vectors have been designed to restrict transgene expression to one or several lineages. For example, specific regulatory elements have been used for targeted expression within erythroid, T, antigen-presenting and myeloid cells, respectively. [15] [16] [17] [18] Notably, Moreau et al. showed that LV incorporating the regulatory sequences from the human CD19 promoter allowed preferential transgene expression in B-lineage cells. 19 Importantly, addition of the immunoglobulin heavy chain μ intronic enhancer (Eμ) and its associated matrix attachment regions both significantly increased gene expression and promoted uniformity of expression compared with either the PGK 20 or CD19 minimal promoters alone. 21, 22 However, the levels of expression obtained with the B-restricted LV reported to date are low in comparison with that mediated by promiscuous γ-retroviral-derived enhancer/promoter elements. Thus, it has remained unclear as to whether candidate B cell-specific LV will mediate transgene expression at levels that will restore function in B-lineage disorders, an important consideration as low levels of B-lineage Btk expression is insufficient to rescue murine models of XLA. 23, 24 In the studies described here, we sought to design LVs that will mimic the expression pattern of endogenous Btk, with the ultimate goal of utilizing such constructs for gene therapy in XLA patients. We generated LV containing three alternative B cell-specific internal enhancer/promoters and evaluated their ability to drive enhanced green fluorescent protein (eGFP) reporter gene expression. As a reference point, we compared the specificity of expression driven by these elements to a previously described B cell-specific LV, EμS. CD19. 21 In parallel, each was compared to a LV containing a strong murine leukemia virus-derived, enhancer/promoter, myeloproliferative sarcoma virus enhancer, negative control region deleted, dl587rev primer-binding site substituted (MND), capable of driving high-level transgene expression in all hematopoietic lineages, 25 and used in a recent successful LV clinical trial.
14 LVs were compared with respect to relative expression in cell lines and primary murine and human cells at low viral copy number. We found that both EμB29 and EμBtkp LV preferentially direct high-level, sustained, transgene expression in immature and mature B lymphoid cells, and support future testing of these constructs in XLA gene therapy models.
results design of B-lineage targeted lV
As shown schematically in Figure 1 , we generated a number of LV-containing alternative enhancer/promoter elements within the parental pRRL backbone. 9 The first, MND-eGFP, incorporated a ubiquitous, γ-retroviral enhancer/promoter. In comparison to other mammalian-derived ubiquitous elements such as elongation factor 1α or PGK, MND drives much higher expression levels in primary murine and human cells providing a benchmark for very high-level gene expression (data not shown). Second, we generated a construct equivalent to the previously reported, B cell-specific vector, EμS.CD19, 19 comprised of the minimal CD19 promoter (230 bp) in conjunction with the Eμ enhancer. While it has been reported that inclusion of a larger portion of the CD19 promoter element (1,274 bp-designated EμL.CD19) generates higher expression levels in B cells, we found little difference in expression levels between these promoters when in association with Eμ (Supplementary Figure S1a) . Next, we generated EμB29-eGFP LV, which contains the B29 (Igβ, CD79b) minimal promoter element 26 in association with the murine immunoglobulin heavy chain, intronic enhancer, Eμ.
27 B29, a key signaling component of the B cell antigen receptor, is initially expressed in pro-B cells and its expression increases in immature/mature B cells. 26, 28, 29 Because the B29 promoter alone exhibited only low-level basal expression (data not shown), the Eμ enhancer was added to increase activity in maturing B cells. The total size of the enhancer/promoter elements for EμB29 and EμS.CD19 were nearly identical. Finally, we created two unique LV constructs designated Btkp-eGFP and EμBtkp-eGFP, that contain regulatory elements derived from the human BTK locus either alone or in combination with the Eμ enhancer, respectively. The 37 kb BTK locus is comprised of 19 exons at Xq22. 30, 31 Transcriptional start sites of human Btk were previously identified within −5 and −30 bp of exon 1 with a minimal promoter critical for lineage-restricted expression between −200 and −1 bp from the transcriptional start site. [32] [33] [34] Additional reporter studies implicated putative regulatory elements between −450 and −200, as well as two conserved NF-κB binding sites within −800 to −600, as positive regulators of Btk expression. 35 We therefore used the first 788 bp of the Btk promoter including these elements, hypothesizing that Btkp, in conjunction with the Eμ enhancer, might provide strong B cell-predominant expression and also retain endogenous control elements essential for lineageappropriate Btk expression.
eµB29 lV drives B-lineage predominant expression that increases with cell maturation
We first compared the expression of eGFP driven by EμB29, EμS. CD19, and MND LV in human T (Jurkat), myeloid (K562), and B cell lines including a panel of different B developmental stages: pro-B (REH), pre-B (Blin and Nalm6), immature B (Ramos), and mature B (Raji) cells. Transduction rates were adjusted via matching eGFP marking to ~10-15% in order to evaluate expression mediated by mostly single viral-integration. In this setting, eGFP mean fluorescent intensity (MFI) provides a direct measure of relative promoter strength. Compared to MND, both EμB29 and EμS.CD19 LV exhibited B cell-predominant eGFP expression with the highest expression levels in more mature B cell lines (Figure 2) Figure 1 schematic of lentiviral constructs. LV were constructed using a pRRL backbone containing an enhancer-deleted U3 region to generate a self-inactivating (SIN) LTR and differ only in their internal promoter/ enhancer region. MND is a retroviral LTR-derived ubiquitous promoter that drives transgene expression in most hematopoietic lineages. Both EμS.CD19-eGFP and EμL.CD19-eGFP employ regulatory sequences from human CD19 and EμB29-eGFP utilizes a murine B29 minimal promoter. Btkp-eGFP LV and EμBtkp-eGFP LV contain a788 bp element derived from endogenous human BTK locus (described in Materials and Methods section). EμB29, EμS.CD19, EμL.CD19, and EμBtkp each also include the murine immunoglobulin intronic enhancer, Eμ. Btk, Bruton's tyrosine kinase; eGFP, enhanced green fluorescent protein; LV, lentiviral vectors; LTR, long-terminal repeats; MND, myeloproliferative sarcoma virus enhancer, negative control region deleted, dl587rev primer-binding site substituted; wPRE, woodchuck hepatitis virus posttranscriptional regulatory element.
EμL.CD19 LV) resulted in slightly higher levels of eGFP compared with EμS.CD19 LV (Supplementary Figure S1a) . However, the expression level for both constructs remained significantly lower than EμB29 LV (Supplementary Figure S1b ). eµB29 drives high-level eGFP expression in primary murine B-lymphocytes To assess expression and lineage specificity in vivo, congenically marked, B6.Ly5.1 recipient mice were lethally irradiated and transplanted with B6.Ly5.2, Lin − HSC transduced with either: MNDeGFP; EμS.CD19-eGFP; or EμB29-eGFP LV. Mice with donor chimerism of >90% were sacrificed 25 weeks post-transplant and spleen and bone marrow (BM) cells analyzed for relative eGFP expression in myeloid and lymphocyte subsets (Figures 3 and 4) . Figure 3a ,b shows representative data from a single experiment (3-5 recipients/group). Of note, the MFI of eGFP expression across independent experiments was influenced by differences in the instrument used for analysis and/or the voltage settings of the laser used to detect eGFP (488 nm argon). While this limited our ability to present a combined dataset, we observed consistent relative differences among our panel of LV constructs in multiple experiments. For comparison, the results from a second independent experiment are displayed in Figure 3c (Figure 3d) . Furthermore, although both LV lead to B cell-predominant expression, nearly all EμB29 recipients exhibited approximately fourfold higher MFI in B cells compared with EμS.CD19 (Figure 3b,c) . One EμB29 recipient animal (in experiment #1) exhibited eGFP expression levels similar to that present in EμS.CD19 recipients; and this result correlated with the lowest viral copy number among the eight EμB29 animals shown. By comparison, MND LV exhibited similar, albeit variable, eGFP expression in all lineages. Average viral copy numbers were similar in all LV cohorts (Figure 3e) indicating that differential LV promoter activity did not reflect altered transduction efficiency.
We next determined whether LV-mediated expression was modulated during BM and/or peripheral B cell development and selection (Figure 4) . Figure 4a shows representative FACS plots of eGFP expression in developing BM B cells. The subsets of developing B cells were gated-based CD43, IgM and IgD expression as described in the figure legend. eGFP MFI was significantly higher in all BM B cells derived from EμB29-eGFP compared to EμS.CD19-eGFP recipients (Figure 4a ) and increased as cells matured from the pro-to mature B cell stage in EμB29 LV recipients (Figure 4b ). In contrast, there was little or no change in eGFP MFI in EμS.CD19-eGFP recipients and MND-eGFP recipients exhibited greater variability with a trend for reduced expression in mature cells. Splenic transitional 1 and 2 (T1 and T2), follicular mature, and marginal zone/marginal zone precursor B cells were identified based on of CD21 and CD24 expression within B220 + B cells 36 and eGFP expression in each subset determined (Figure 4c ). Most MND-eGFP LV recipients exhibited a decline, and EμS.CD19 LV recipients little or no change, in relative eGFP MFI in immature versus more mature B cells, respectively. In contrast, the majority of EμB29-LV recipients exhibited a consistent increase in eGFP MFI in more mature, follicular mature, and marginal zone/marginal zone precursor, compared to less mature, T1 B cells. Thus, EμB29-LV drives high-level B predominant expression that increases with B cell maturation.
eµB29 mediates high-level B-lineage expression in primary human B-lymphocytes
We also examined the activity of candidate LV in primary human cells derived from transduced HSC. We utilized a NOD/SCID/ γc − / − (NSG) xenograft system in which MND-eGFP, EμS.CD19-eGFP or EμB29-eGFP LV transduced human cord blood CD34 + cells were transplanted into recipient immune-deficient NSG mice. 37, 38 Engrafted mice were sacrificed at 20-25 weeks posttransplant and human-derived, BM and splenic hematopoietic subsets were analyzed for relative eGFP expression ( to B cell-predominant eGFP expression with lower expression in T and myeloid cells (Figure 5b-d) . Although substantial variation was observed among individual recipients, the average level of eGFP expression in B cells was fourfold higher for EμB29 compared to EμS.CD19 LV. Viral copy numbers were similar in all experimental groups (Figure 5e) .
The cell surface marker, CD10, is expressed specifically on immature human B cells. 39 We therefore evaluated relative eGFP expression in immature CD10 + versus more mature CD10 − CD19 + BM B cells in recipient NSG mice. EμB29-eGFP LV recipients exhibited a progressive increase in eGFP MFI in CD10 − compared to CD10 + B cells (Figure 6a) . In contrast, little difference was observed in EμS.CD19 recipients, and MND LV recipients exhibited a decline in eGFP MFI in CD10 − cells. Immature, splenic CD24 hi CD38
hi B cells in NSG recipients also express CD10, 40 immune disorder, XLA, we generated LV containing regulatory elements derived from the human BTK locus. As described above (Figure 1) , we generated Btkp and EμBtkp LV and compared these constructs with our best-performing, B-lineage expression vector, EμB29 LV, in murine and human-based in vivo models. First, we established mouse BM chimeras using HSC transduced with EμB29-eGFP, Btkp-eGFP, or EμBtkp-eGFP LV using the same methods as Figure 3 . Recipient mice were sacrificed at 25 weeks post-transplant and the relative percentage and intensity of eGFP expression assessed within various BM (data not shown) and splenic populations (Figure 7) . As in Figure 3 , due to differences in the 488-nm argon laser voltage settings, the results from two independent experiments are shown (Figure 7b,c) . Again, while overall eGFP MFI differed between experiments, we observed consistent results with respect to the panel of LV vectors. Representative FACS plots for both experiments are also shown in Supplementary Figure S2 (as experiment #3 and 4, respectively). EμBtkp LV-mediated high-level eGFP expression in splenic B cells, although by comparison EμB29 LV showed a slightly higher MFI in most animals (Figure 7a-c) . In contrast, expression in B cells using Btkp LV was tenfold lower level than Eμ enhancer containing LV. As anticipated, only low-level eGFP expression was present in T cells. Consistent with its lower activity in B cells, the relative T:B cell expression ratio was ~0. 35 (approximately threefold less) for Btkp versus ~0.05 (~20-fold less) for EμBtkp and EμB29 (Figure 7d) . Consistent with the expression pattern of endogenous Btk, Btkp LV mediated similar levels of eGFP in B and myeloid cells. This feature was most evident when the MFI of eGFP in monocytes or neutrophils was analyzed as a ratio relative to the MFI in B cells (Figure 7d ). The monocyte:B and the neutrophil:B expression ratios for Btkp LV were close to 1.0. An increase in myeloid expression ratio was also evident, albeit to a lesser degree, with EμBtkp when compared to EμB29 LV. In contrast, EμB29 expressed eGFP at significantly lower levels in monocytes or neutrophils versus B cells. All recipient animals exhibited similar viral copy numbers (Figure 7e) .
To assess LV function in human primary cells, cord blood CD34 + HSC were transduced with EμB29-eGFP, Btkp-eGFP, or EμBtkp-eGFP LV and transplanted into NSG recipient mice. Overall, the expression pattern in splenic-derived human cells mirrored those from the murine chimeric setting (Figure 8) . EμBtkp LV drove high-level eGFP expression in human B cells whereas in Btkp LV eGFP expression was at least fivefold lower. Combined data from several experiments showed high-level, albeit variable, B cell expression for both EμB29 and EμBtkp LV (Figure 8b) . T cell expression was very low in all recipients with a B:T cell expression ratio as high as 60 in some EμBtkp recipients. In contrast to EμB29, EμBtkp LV also led to intermediate levels of transgene expression in monocytes. However, because expression was variable this data did not reach statistical significance for the number of animals studied. As in murine studies, Btkp LV exhibited consistent, low-level eGFP expression in both B cells and monocytes. All recipient animals exhibited similar average viral copy numbers (Figure 8c) .
Collectively, these data demonstrate that EμBtkp LV mediates high-level transgene expression in primary murine and human B cells, presumably facilitated by the Eμ element; and also drives intermediate levels of transgene expression in myeloid cells in a manner analogous to the endogenous Btk promoter.
dIscussIon
Successful LV-based HSC gene therapy requires efficient gene transfer into multipotent HSC followed by sustained, therapeutic levels of transgene expression within key target cell populations. This study focused on developing LV that facilitate gene expression in developing and mature B-lineage cells for use in candidate B-lineage disorders. Our data demonstrate efficient, B cell-predominant gene expression using LV vectors containing two distinct promoter/ enhancer combinations. Our initial studies focused on the composite vector, EμB29. This construct mediated high-level reporter transgene expression in multiple human B cell lines and in both human and mouse primary B cells derived from transduced HSC. In contrast to previous observations showing highly variable B-lineage expression following HSC transduction using γ retroviral vectors, 42 cell differentiation did not lead to appreciable evidence for silencing or variegation of EμB29 LV. Consistent with this interpretation, sustained eGFP expression was observed in both immature and mature B cells for at least 20 weeks despite low-level viral marking (<1.5 copies/cell). Notably, EμB29 LV exhibited significantly higher levels of reporter gene expression than EμS.CD19 LV, even though both LV contained minimal promoters activated at nearly identical points following B-lineage commitment. EμB29 LV expression also increased progressively in parallel with BM B cell differentiation in both murine and human models and was maintained in the peripheral B lymphoid compartment. Expression levels were further increased during splenic transitional development, leading to highest expression within mature murine marginal zone and follicular mature B cells, and CD10 − human B cells, respectively. By contrast, EμS.CD19 LV exhibited lower level, stable expression levels throughout BM and peripheral B cell development. Together these data suggest that EμB29 LV might be useful for clinical disorders where progressively higher levels of transgene expression are required in developing and mature B cells. Although we observed some variability in expression levels of eGFP driven by EμB29 LV in both the murine and human stem cell models, the overall trend for higher-level transgene expression (compared to EμS.CD19) suggests that this promoter would be a superior choice for B cell-specific expression. Notably, previous work has shown that subendogenous Btk expression levels are insufficient to mediate functional rescue of mature B cells Btk-deficient mice. 23, 24 Based on these ideas, we recently evaluated ex-vivo gene therapy in a murine model of XLA using the EμB29 LV to deliver human Btk. This approach lead to near-complete developmental and functional B cell rescue. 43 Importantly, our findings paralleled earlier work from our group using a highly active, ubiquitously expressed, murine stem cell virus-based γ retroviral vector. 5 Thus, equivalent clinical efficacy was achieved via this unique B-lineage targeted, potentially safer, LV delivery platform.
Despite its efficacy in the murine XLA model, the EμB29 enhancer/promoter may not be ideal for cell-specific Btk expression. Notably, while its functional role is most evident in B cells, Btk is also expressed in all myeloid subsets and megakaryocytes; and Btk also impacts signaling via a range of cell surface receptors. 3, 44 Recent work has demonstrated a requirement for Btk kinases in Toll-like receptor signals [45] [46] [47] implying that Btk deficiency may impact innate, as well as adaptive, immune responses in vivo. Based on these considerations, we generated LV constructs containing the endogenous BTK promoter. As anticipated, Btkp LV exhibited sustained, albeit low-level activity in primary murine and human B and myeloid cells. Importantly, addition of the Eμ enhancer lead to a marked increase in relative B-lineage expression, with activity levels closely mimicking EμB29 LV in both murine and human primary B cells. In contrast to EμB29 LV, however, EμBtkp LV also retained modest transgene expression in myeloid populations suggesting this LV may more faithfully mimic endogenous Btk expression and potentially rescue Btk-dependent myeloid activity.
Taken together, our data indicate that EμB29 LV provides an efficient platform for high-level mammalian B cell gene expression. Furthermore, these data also suggest that EμBtkp LV may represent an optimal system for regulated Btk gene delivery in XLA. This latter possibility is currently being investigated using murine models of XLA. Finally, it is important to note that we observed no evidence for Eμ enhancer-dependent mutagenesis in this study or in >200 primary/secondary/or tertiary recipient mice treated to date using these LV for Btk delivery. Formal studies, however, using genome targeted integration 48 and BM immortalization assays 49 will be required to more fully address the potential risk(s) of these new LV constructs.
MaterIals and Methods
LV constructs and viral production. The parental pRRL-SIN-cppt-PGKeGFP-WPRE vector 9 was obtained from Didier Trono (Addgene plasmid #12252) and the internal PGK promoter was replaced to generate pRRL-EµB29-eGFP, pRRL-EμBtkp-eGFP, pRRL-MND-eGFP, or pRRL-EµCD19-eGFP. MND is a retroviral long-terminal repeats-derived promoter. 50 The immunoglobulin μ heavy chain enhancer Eµ is comprised of the 1-kb murine Ig heavy chain intronic core enhancer and the 5′ and 3′ matrix attachment region elements 27 and was added to all other promoters except MND and Btkp alone. B29 contained the minimal promoter element derived from the B29 gene comprising 184 bp of the murine promoter including −166 to +18 from the major transcriptional start site. 26 S.CD19 and L.CD19 contained the minimal (204 bp) versus extended (1,224 bp), human CD19 promoter element and adjacent upstream enhancer region, respectively. 19 Btkp contains a 788 bp sequence located directly upstream of exon 1 within the human BTK locus. LV were produced by transient transfection of 293T cells using PEI method, concentrated by low-speed centrifugation, and titered as described previously.
43
Cell culture and transduction. The following cell lines were utilized for lentiviral transduction experiments; Blin and Nalm6 (gift from Dr Tucker LeBien, University of Minnesota, Minneapolis, MN), REH, Ramos, Raji, Jurkat, and K562 (ATCC, Manassas, VA). All cells were maintained in complete RPMI (RPMI plus l-glutamine, 10% fetal bovine serum, 0.1% β-mercaptoethanol and 10 μmol/l HEPES) media and transduced with the indicated lentiviral construct overnight with 4 μg/ml polybrene at variable multiplicity of infection's to obtain similar transduction rate (from 10 to 15%). Cells were incubated for 4 days and the MFI of eGFP was determined via flow cytometer.
Murine BM transplantation. C57BL/6 mice were bred and maintained in the specific pathogen-free barrier facilities at Seattle Children's Research Institute. Animal studies were carried out according to the guidelines of Seattle Children's Research Institute Institutional Animal Care and Use Committee. BM from 6 to 8 weeks mice was harvested and Lin − cells were obtained using EasySep Mouse Hematopoietic Progenitor Cell Enrichment kit according to manufacture's instruction (StemCell Technologies, Vancouver, BC), transduced overnight in media (StemSpan SFEM, StemCell Technologies) containing mSCF and mTPO (10 μg/ml; PeproTech, Rocky Hills, NJ) with the indicated LV overnight with 4 μg/ ml polybrene. Cells were washed, counted, and 1 × 10 6 transduced cells were transplanted into mice receiving 2 × 500 Gy total body irradiation conditioning. Recipient mice were evaluated by serial peripheral blood analyses beginning at 5 weeks, and cohorts were sacrificed at 24-26 weeks for detailed analyses.
Cord blood CD34 + cell isolation, transduction, and transplantation of NSG recipients. Human umbilical cord blood was obtained from the Puget Sound Blood Center cord blood donor program and CD34 + cells were isolated using Miltenyi CD34 + beads (Miltenyi, Biotec, Germany) according to the manufacturer's instructions. Purity of CD34 + Lineage − cells was >90% in all experiments. CD34 + cells were incubated for 8-12 hours in IMDM with human cytokines (100 ng/ml SCF, TPO, and FLT3-L; PeproTech) and 5% fetal bovine serum. After incubation, cells were transduced with the indicated LV at an multiplicity of infection of 10 for 8 hours in media with cytokines and 4 μg/ml polybrene. Transduced CD34 + cells were washed and transplanted into NOD/SCID/cγ −/− (NSG) mice. For all experiments, 6-12 weeks recipient mice were conditioned with 250 cGy total body irradiation and transplanted with 2-3 × 10 5 transduced, or mock transduced, CD34 + cells via retro-orbital injection. Peripheral blood samples were obtained from recipients 8 weeks after transplantation and the level of HSC engraftment was accessed via CD45 expression. Cohorts were sacrificed at 20-30 weeks for detailed FACS analysis of BM and spleen.
Flow cytometric analysis. Single-cell suspensions prepared from BM or spleen were incubated in phosphate-buffered saline with 3% fetal calf serum and fluorochrome-conjugated antibodies for 20 minutes at 4 °C, and washed twice before resuspension in phosphate-buffered saline with 3% fetal calf serum for acquisition. The following antibodies were used: antihuman CD19, CD33, CD45, IgM, IgD, 38, CD24, CD10, CD34, antimouse CD3, CD4, CD8, B220, CD21, CD24, CD43, IgM, IgD, Gr-1, CD11b, and CD45.1 (BD Biosciences, San Jose, CA and eBioscience, San Diego, CA). Cell analysis were performed using FACSCalibur, Aria II, and LSRII flow cytometers (BD Biosciences) and FlowJo software (Tree Star, Ashland, OR). Viral copy number determination. Quantification of viral integration was adapted from a previously described protocol. 5 Briefly, genomic DNA was obtained from spleen or total BM from sacrificed animals. Gag-specific primer/probe sets were used to amplify viral integrations in both mouse and human cells. To normalize DNA content in mouse cells, a murine β-actin primer/probe set was used; in human cells, a human RNaseP primer probe set was used (Applied Biosytems, Carlsbad, CA). Viralintegration number was determined via a standard curve established using genomic DNA extracted from A20 murine B cell line or Nalm6 human B cell line, each containing a single LV integration.
Statistical analysis. Statistical analyses of relative eGFP marking and viral copy numbers were carried out using a two-tailed paired Student's t test comparing the indicated cell populations from the groups of experimental mice or cell lines. 
